Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 8252980, 8 pages
https://doi.org/10.1155/2017/8252980
Research Article

Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard

1Gastroenterology and Hepatology Department, University of the State of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
2Gastroenterology and Hepatology Department, Bonsucesso Federal Hospital, Rio de Janeiro, RJ, Brazil
3Laboratory of Clinical Research in HIV, AIDS and STD (LAPCLIN-AIDS), National Institute of Infectious Diseases Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil
4Rheumatology Department, Federal University of São Paulo, São Paulo, SP, Brazil
5Department of Research and Development, Fleury Group, São Paulo, SP, Brazil
6Gastroenterology Department, Federal University of São Paulo, São Paulo, SP, Brazil
7D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil

Correspondence should be addressed to Hugo Perazzo; rb.zurcoif.ini@ozzarep.oguh

Received 31 March 2017; Revised 30 July 2017; Accepted 3 August 2017; Published 13 September 2017

Academic Editor: Paola Di Carlo

Copyright © 2017 Flavia F. Fernandes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Table 1: Performance of tests as estimated by classical 2 x 2 analysis (liver biopsy as gold standard) and Latent Class Analysis (without gold standard) using APRI's cut-off > 0.5 and > 1.0 for diagnosis of significant fibrosis (F≥2) and cirrhosis (F=4), respectively.

Supplementary Table 2: Sensitivities and specificities of tests for diagnosis of significant fibrosis (F≥2) and cirrhosis (F=4) as estimated by Latent Class Analysis in models with co-linearity between non-invasive methods.

Supplementary Table 3: Diagnostic performance of non-invasive tests for diagnosis of significant fibrosis (F≥2) and cirrhosis (F=4) in obese patients (BMI ≥ 30Kg/m2) (n=30).

Supplementary Figure 1: Area under the ROC curve (AUROC) for diagnosis of significant fibrosis (F≥2) of (A) transient elastography (TE), (B) Aspartate-to-Platelet-Ratio-Index (APRI) and (C) Enhanced Liver Fibrosis (ELF) using liver biopsy as the reference.

Supplementary Figure 2: Area under the ROC curve (AUROC) for diagnosis of cirrhosis (F=4) of (A) transient elastography (TE), (B) Aspartate-to-Platelet-Ratio-Index (APRI) and (C) Enhanced Liver Fibrosis (ELF) using liver biopsy as the reference.

  1. Supplementary Material